Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study.
Sarma M, Perimbeti S, Nasir S, Attwood K, Kapoor A, O'Connor T, Early A, Levine EG, Takabe K, Kalinski P, Ambrosone C, Khoury T, Yao S, Gandhi S. Sarma M, et al. Among authors: early a. Breast Cancer Res Treat. 2022 Apr;192(2):411-421. doi: 10.1007/s10549-021-06506-y. Epub 2022 Jan 9. Breast Cancer Res Treat. 2022. PMID: 35000093 Free PMC article.
Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
Dhakal A, Matthews CM, Levine EG, Salerno KE, Zhang F, Takabe K, Early AP, Edge SB, O'Connor T, Khoury T, Young JS, Opyrchal M. Dhakal A, et al. Among authors: early ap. Clin Breast Cancer. 2018 Dec;18(6):e1401-e1405. doi: 10.1016/j.clbc.2018.04.015. Epub 2018 Apr 28. Clin Breast Cancer. 2018. PMID: 29778787 Free PMC article. Clinical Trial.
Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib.
Dhakal A, Antony Thomas R, Levine EG, Brufsky A, Takabe K, Hanna MG, Attwood K, Miller A, Khoury T, Early AP, Soniwala S, O'Connor T, Opyrchal M. Dhakal A, et al. Among authors: early ap. Breast Cancer (Auckl). 2020 Jul 23;14:1178223420944864. doi: 10.1177/1178223420944864. eCollection 2020. Breast Cancer (Auckl). 2020. PMID: 32753876 Free PMC article.
CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin.
Lang JK, Karthikeyan B, Quiñones-Lombraña A, Blair RH, Early AP, Levine EG, Sharma UC, Blanco JG, O'Connor T. Lang JK, et al. Among authors: early ap. Cardiooncology. 2021 May 11;7(1):17. doi: 10.1186/s40959-021-00103-0. Cardiooncology. 2021. PMID: 33975650 Free PMC article.
Patients homozygous for the CBR3 V244M G allele (CBR3 V244) exhibited a further statistically significant decrease in LVEF at 6 months following DOX therapy in comparison with patients with heterozygous AG genotype. ...CONCLUSIONS: CBR3 V244M genotype status is associated …
Patients homozygous for the CBR3 V244M G allele (CBR3 V244) exhibited a further statistically significant decrease in LVEF at 6 month …
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx.
Gandhi S, Opyrchal M, Grimm MJ, Slomba RT, Kokolus KM, Witkiewicz A, Attwood K, Groman A, Williams L, Tarquini ML, Wallace PK, Soh KT, Minderman H, Maguire O, O'Connor TL, Early AP, Levine EG, Kalinski P. Gandhi S, et al. Among authors: early ap. J Immunother Cancer. 2023 Nov;11(11):e007381. doi: 10.1136/jitc-2023-007381. J Immunother Cancer. 2023. PMID: 37963636 Free PMC article.
126 results